Jump to content

Semaglutide: Difference between revisions

From Pharmacopedia
Pharmacopedia
BrowseCategoriesLog in
[unchecked revision][checked revision]
← Older edit

MDElliottMD (talk | contribs)

3 user groups
5,673 edits
VisualWikitext
Backfill inline <ref> citations per new sitewide citation rule
Strip Category:MedCategory marker per interface-claude 2026-05-20 hygiene order: this page is a medicine, narrative, wiki-meta page, or stylesheet rather than a class-overview category, so it should not carry the MedCategory tag. Class memberships and other tags preserved.
 
(4 intermediate revisions by the same user not shown)
Line 2: Line 2:
| generic = Semaglutide
| generic = Semaglutide
| brand = Ozempic (T2DM SC), Wegovy (obesity SC), Rybelsus (oral T2DM)
| brand = Ozempic (T2DM SC), Wegovy (obesity SC), Rybelsus (oral T2DM)
| structure = 31-amino-acid acylated peptide analog of human [[GLP-1]] (7–37), with Aib substitution at position 8 (blocks DPP-4 cleavage) and a C18 fatty diacid linked via γGlu-2×OEG spacer at Lys26 (drives albumin binding → ~165 h half-life)<ref name="lau2015">Lau J, Bloch P, Schäffer L et al. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. ''J Med Chem'' 58(18):7370–80. doi:10.1021/acs.jmedchem.5b00726</ref>
| structure =  
 
| classes = [[GLP-1 receptor agonist]] · [[Antidiabetic medicines|Antidiabetic]] · [[Anti-obesity medicines|Anti-obesity]] · [[Cardiovascular risk reduction]] agent
| classes = [[GLP-1 receptor agonist]] · [[Antidiabetic medicines|Antidiabetic]] · [[Anti-obesity medicines|Anti-obesity]] · [[Cardiovascular risk reduction]] agent
| mechanism = Selective long-acting agonist of the [[GLP-1 receptor]] (class B GPCR). Produces glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, hypothalamic appetite suppression, and direct cardiovascular and renal protective effects.<ref name="drucker2022">Drucker DJ (2022). GLP-1 physiology informs the pharmacotherapy of obesity. ''Mol Metab'' 57:101351. doi:10.1016/j.molmet.2021.101351</ref>
| mechanism = Long-acting agonist of the [[GLP-1 receptor]].
 
| uses = [[Type 2 diabetes mellitus]] · [[Obesity]] · [[Cardiovascular risk reduction]] in obesity without diabetes · [[MASH]] with stage 2–3 fibrosis · [[Chronic kidney disease]] in T2DM
| uses = [[Type 2 diabetes mellitus]] · [[Obesity]] · [[Cardiovascular risk reduction]] in obesity without diabetes · [[MASH]] with stage 2–3 fibrosis · [[Chronic kidney disease]] in T2DM
| starting_dose = Ozempic: 0.25 mg SC weekly × 4 wk<ref name="ozempic-label">US FDA. ''Ozempic (semaglutide) prescribing information.'' Novo Nordisk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s019lbl.pdf</ref> · Wegovy: 0.25 mg SC weekly × 4 wk<ref name="wegovy-label">US FDA. ''Wegovy (semaglutide) prescribing information.'' Novo Nordisk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf</ref> · Rybelsus: 3 mg PO daily × 30 d<ref name="rybelsus-label">US FDA. ''Rybelsus (semaglutide) prescribing information.'' Novo Nordisk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf</ref>
| starting_dose = Ozempic: 0.25 mg SC weekly × 4 wk<ref name="ozempic-label">US FDA. ''Ozempic (semaglutide) prescribing information.'' Novo Nordisk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s019lbl.pdf</ref> · Wegovy: 0.25 mg SC weekly × 4 wk<ref name="wegovy-label">US FDA. ''Wegovy (semaglutide) prescribing information.'' Novo Nordisk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf</ref> · Rybelsus: 3 mg PO daily × 30 d<ref name="rybelsus-label">US FDA. ''Rybelsus (semaglutide) prescribing information.'' Novo Nordisk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf</ref>
Line 12: Line 14:
| onset = Glycemic effect within days;{{Citation needed}} full weight effect over months<ref name="step1">Wilding JPH et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP-1). ''NEJM'' 384:989. doi:10.1056/NEJMoa2032183</ref>
| onset = Glycemic effect within days;{{Citation needed}} full weight effect over months<ref name="step1">Wilding JPH et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP-1). ''NEJM'' 384:989. doi:10.1056/NEJMoa2032183</ref>
| duration = ~7 days (weekly SC dosing)<ref name="ozempic-label"/> · ~24 h (oral)<ref name="rybelsus-label"/>
| duration = ~7 days (weekly SC dosing)<ref name="ozempic-label"/> · ~24 h (oral)<ref name="rybelsus-label"/>
| halflife = ~165 hours (~1 week) — among the longest of any GLP-1 RA<ref name="lau2015"/>
| halflife = ~165 hours (~1 week), among the longest of any GLP-1 RA<ref name="lau2015"/>
| bioavailability = SC ~89%{{Citation needed}} · Oral ~0.4–1% (SNAC-enhanced)<ref name="rybelsus-label"/>
| bioavailability = SC ~89%{{Citation needed}} · Oral ~0.4–1% (SNAC-enhanced)<ref name="rybelsus-label"/>
| pregnancy = Avoid. Discontinue ≥2 months before planned pregnancy due to long half-life. Animal data show embryofetal harm.<ref name="ozempic-label"/> Not contraceptive — but rapid weight loss + improved ovulation may unmask fertility in [[PCOS]].{{Citation needed}}
| pregnancy = Avoid. Discontinue ≥2 months before planned pregnancy due to long half-life. Animal data show embryofetal harm.<ref name="ozempic-label"/> Not contraceptive, but rapid weight loss + improved ovulation may unmask fertility in [[PCOS]].{{Citation needed}}
| legal = Rx-only;<ref name="ozempic-label"/> not a controlled substance
| legal = Rx-only;<ref name="ozempic-label"/> not a controlled substance
| intro = Semaglutide is a long-acting [[GLP-1 receptor agonist]] developed by [[Novo Nordisk]], marketed as '''[[Ozempic]]''' (weekly subcutaneous, for [[type 2 diabetes mellitus]]),<ref name="ozempic-label"/> '''[[Wegovy]]''' (weekly subcutaneous, for [[obesity]], [[cardiovascular risk reduction]] in obesity without diabetes, and [[MASH]] with fibrosis),<ref name="wegovy-label"/><ref name="select">Lincoff AM et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). ''NEJM'' 389:2221–32. doi:10.1056/NEJMoa2307563</ref><ref name="essence">Newsome PN et al. (2025). Semaglutide in MASH (ESSENCE). FDA approval basis. {{Citation needed}}</ref> and '''[[Rybelsus]]''' (daily oral tablet, for T2DM).<ref name="rybelsus-label"/> It is, by revenue, among the highest-grossing medicines on the planet as of 2024.{{Citation needed}}
| intro = Semaglutide is a long-acting [[GLP-1 receptor agonist]] developed by [[Novo Nordisk]], marketed as '''[[Ozempic]]''' (weekly subcutaneous, for [[type 2 diabetes mellitus]]),<ref name="ozempic-label"/> '''[[Wegovy]]''' (weekly subcutaneous, for [[obesity]], [[cardiovascular risk reduction]] in obesity without diabetes, and [[MASH]] with fibrosis),<ref name="wegovy-label"/><ref name="select">Lincoff AM et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). ''NEJM'' 389:2221–32. doi:10.1056/NEJMoa2307563</ref><ref name="essence">Newsome PN et al. (2025). Semaglutide in MASH (ESSENCE). FDA approval basis. {{Citation needed}}</ref> and '''[[Rybelsus]]''' (daily oral tablet, for T2DM).<ref name="rybelsus-label"/> It is, by revenue, among the highest-grossing medicines on the planet as of 2024.{{Citation needed}}
Line 20: Line 22:
Semaglutide is the second weekly GLP-1 RA from Novo Nordisk's incretin program (after [[liraglutide]])<ref name="lau2015"/> and the molecule that, more than any other, made obesity treatment a mainstream rather than a specialty intervention.{{Citation needed}}
Semaglutide is the second weekly GLP-1 RA from Novo Nordisk's incretin program (after [[liraglutide]])<ref name="lau2015"/> and the molecule that, more than any other, made obesity treatment a mainstream rather than a specialty intervention.{{Citation needed}}


| pharmacokinetics = Acylation with a C18 fatty diacid drives non-covalent binding to serum albumin, slowing renal clearance and DPP-4 access. The Aib8 substitution renders the peptide DPP-4-resistant. Resulting terminal half-life ~165 h means once-weekly subcutaneous dosing produces near-steady-state plasma levels.<ref name="lau2015"/>
| pharmacokinetics = '''Chemistry'''. 31-amino-acid acylated peptide analog of human [[GLP-1]] (7–37), with Aib substitution at position 8 (blocks DPP-4 cleavage) and a C18 fatty diacid linked via γGlu-2×OEG spacer at Lys26 (drives albumin binding → ~165 h half-life)<ref name="lau2015">Lau J, Bloch P, Schäffer L et al. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. ''J Med Chem'' 58(18):7370–80. doi:10.1021/acs.jmedchem.5b00726</ref>
 
Acylation with a C18 fatty diacid drives non-covalent binding to serum albumin, slowing renal clearance and DPP-4 access. The Aib8 substitution renders the peptide DPP-4-resistant. Resulting terminal half-life ~165 h means once-weekly subcutaneous dosing produces near-steady-state plasma levels.<ref name="lau2015"/>


Oral semaglutide (Rybelsus) is co-formulated with '''SNAC''' (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), a permeation enhancer that transiently raises gastric pH and protects the peptide locally — yielding ~0.4–1% bioavailability, which is sufficient at 14 mg daily to match Ozempic 0.5 mg weekly for glycemic effect (but not for weight loss).<ref name="rybelsus-label"/><ref name="buckley2018">Buckley ST, Bækdal TA, Vegge A et al. (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. ''Sci Transl Med'' 10(467):eaar7047. doi:10.1126/scitranslmed.aar7047</ref> Strict fasting administration is mandatory; any concurrent food or beverage destroys absorption.<ref name="rybelsus-label"/>
Oral semaglutide (Rybelsus) is co-formulated with '''SNAC''' (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), a permeation enhancer that transiently raises gastric pH and protects the peptide locally, yielding ~0.4–1% bioavailability, which is sufficient at 14 mg daily to match Ozempic 0.5 mg weekly for glycemic effect (but not for weight loss).<ref name="rybelsus-label"/><ref name="buckley2018">Buckley ST, Bækdal TA, Vegge A et al. (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. ''Sci Transl Med'' 10(467):eaar7047. doi:10.1126/scitranslmed.aar7047</ref> Strict fasting administration is mandatory; any concurrent food or beverage destroys absorption.<ref name="rybelsus-label"/>


Predominantly catabolic clearance via proteolysis; renal and hepatic impairment do not require dose adjustment.<ref name="ozempic-label"/> No CYP-mediated metabolism, so the interaction profile is dominated by ''gastric emptying'' effects on other oral medicines, not pharmacokinetic competition.<ref name="ozempic-label"/>
Predominantly catabolic clearance via proteolysis; renal and hepatic impairment do not require dose adjustment.<ref name="ozempic-label"/> No CYP-mediated metabolism, so the interaction profile is dominated by ''gastric emptying'' effects on other oral medicines, not pharmacokinetic competition.<ref name="ozempic-label"/>


| pharmacodynamics = At maintenance doses semaglutide produces:
| pharmacodynamics = '''Receptor pharmacology'''. Selective long-acting agonist of the [[GLP-1 receptor]] (class B GPCR). Produces glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, hypothalamic appetite suppression, and direct cardiovascular and renal protective effects.<ref name="drucker2022">Drucker DJ (2022). GLP-1 physiology informs the pharmacotherapy of obesity. ''Mol Metab'' 57:101351. doi:10.1016/j.molmet.2021.101351</ref>
 
At maintenance doses semaglutide produces:
* HbA1c reduction of ~1.5–2.0 percentage points (Ozempic 1 mg)<ref name="sustain6">Marso SP et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). ''NEJM'' 375:1834–44. doi:10.1056/NEJMoa1607141</ref>
* HbA1c reduction of ~1.5–2.0 percentage points (Ozempic 1 mg)<ref name="sustain6">Marso SP et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). ''NEJM'' 375:1834–44. doi:10.1056/NEJMoa1607141</ref>
* Weight loss of ~6 kg (Ozempic 1 mg, T2DM)<ref name="sustain6"/> to ~14.9% body weight (Wegovy 2.4 mg, obesity without T2DM, STEP-1)<ref name="step1"/>
* Weight loss of ~6 kg (Ozempic 1 mg, T2DM)<ref name="sustain6"/> to ~14.9% body weight (Wegovy 2.4 mg, obesity without T2DM, STEP-1)<ref name="step1"/>
Line 34: Line 40:
* 24% relative risk reduction in kidney + CV composite in T2DM + CKD (FLOW)<ref name="flow">Perkovic V et al. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). ''NEJM'' 391:109. doi:10.1056/NEJMoa2403347</ref>
* 24% relative risk reduction in kidney + CV composite in T2DM + CKD (FLOW)<ref name="flow">Perkovic V et al. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). ''NEJM'' 391:109. doi:10.1056/NEJMoa2403347</ref>


| indications = <indication ref="diabetes-type-2" author="MDElliottMD"/>
| indications = <problem ref="diabetes-type-2" author="MDElliottMD"/>
<indication ref="obesity" author="MDElliottMD"/>
<problem ref="obesity" author="MDElliottMD"/>
<indication ref="cv-risk-obesity" author="MDElliottMD"/>
<problem ref="cv-risk-obesity" author="MDElliottMD"/>
<indication ref="mash-fibrosis" author="MDElliottMD"/>
<problem ref="mash-fibrosis" author="MDElliottMD"/>
<indication ref="ckd-t2dm" author="MDElliottMD"/>
<problem ref="ckd-t2dm" author="MDElliottMD"/>


| dosing = <titration slug="ozempic-standard" author="MDElliottMD" title="Ozempic — standard T2DM titration">
| dosing = <titration slug="ozempic-standard" author="MDElliottMD" title="Ozempic, standard T2DM titration">
0.25 mg SC weekly × 4 weeks (non-therapeutic; tolerance ramp only)
0.25 mg SC weekly × 4 weeks (non-therapeutic; tolerance ramp only)
→ 0.5 mg SC weekly × ≥4 weeks
→ 0.5 mg SC weekly × ≥4 weeks
Line 46: Line 52:
→ 2 mg SC weekly (max) if needed<ref name="ozempic-label"/>
→ 2 mg SC weekly (max) if needed<ref name="ozempic-label"/>


Slower titration is reasonable in any patient with significant GI symptoms — holding at a tolerated dose for 8–12 weeks before advancing is standard practice.
Slower titration is reasonable in any patient with significant GI symptoms, holding at a tolerated dose for 8–12 weeks before advancing is standard practice.
</titration>
</titration>


<titration slug="wegovy-standard" author="MDElliottMD" title="Wegovy — standard obesity titration">
<titration slug="wegovy-standard" author="MDElliottMD" title="Wegovy, standard obesity titration">
0.25 mg SC weekly × 4 weeks
0.25 mg SC weekly × 4 weeks
→ 0.5 mg × 4 weeks
→ 0.5 mg × 4 weeks
Line 59: Line 65:
</titration>
</titration>


<titration slug="rybelsus-standard" author="MDElliottMD" title="Rybelsus — standard oral T2DM titration">
<titration slug="rybelsus-standard" author="MDElliottMD" title="Rybelsus, standard oral T2DM titration">
3 mg PO daily × 30 days (non-therapeutic ramp)
3 mg PO daily × 30 days (non-therapeutic ramp)
→ 7 mg PO daily × ≥30 days
→ 7 mg PO daily × ≥30 days
Line 68: Line 74:


| effects = Subjective effects vary considerably with dose and titration speed but reliably include:
| effects = Subjective effects vary considerably with dose and titration speed but reliably include:
* '''Early satiety''' — meals feel "complete" at a fraction of prior intake<ref name="step1"/>
* '''Early satiety''', meals feel "complete" at a fraction of prior intake<ref name="step1"/>
* '''Food noise quieting''' — the most commonly volunteered subjective change. Patients report that intrusive food-related thoughts simply stop.{{Citation needed}}
* '''Food noise quieting''', the most commonly volunteered subjective change. Patients report that intrusive food-related thoughts simply stop.{{Citation needed}}
* '''Reduced alcohol craving''' — corroborated by observational and small RCT data; mechanism likely shared with food reward circuitry<ref name="wang2024">Wang W, Volkow ND, Berger NA et al. (2024). Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. ''Nat Commun'' 15:4548. doi:10.1038/s41467-024-48780-6</ref>
* '''Reduced alcohol craving''', corroborated by observational and small RCT data; mechanism likely shared with food reward circuitry<ref name="wang2024">Wang W, Volkow ND, Berger NA et al. (2024). Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. ''Nat Commun'' 15:4548. doi:10.1038/s41467-024-48780-6</ref>
* '''Nausea''' — dose-dependent, worst in first 1–2 weeks of any new dose level<ref name="ozempic-label"/>
* '''Nausea''', dose-dependent, worst in first 1–2 weeks of any new dose level<ref name="ozempic-label"/>
* '''Constipation or diarrhea''' (variable, can alternate)<ref name="ozempic-label"/>
* '''Constipation or diarrhea''' (variable, can alternate)<ref name="ozempic-label"/>
* '''Sulfurous eructation''' (a small but very real subgroup){{Citation needed}}
* '''Sulfurous eructation''' (a small but very real subgroup){{Citation needed}}
Line 84: Line 90:
Importantly: semaglutide is '''not a contraceptive''', and the medicine may '''restore ovulation''' in patients with [[PCOS]] or [[obesity]]-associated anovulation.{{Citation needed}} Patients of childbearing potential should be counseled about contraception ''before'' starting.
Importantly: semaglutide is '''not a contraceptive''', and the medicine may '''restore ovulation''' in patients with [[PCOS]] or [[obesity]]-associated anovulation.{{Citation needed}} Patients of childbearing potential should be counseled about contraception ''before'' starting.


| monitoring = * Baseline: HbA1c, weight, BP, renal function, lipid panel, [[ALT]]/AST (especially for MASH indication)
| monitoring = * Baseline: HbA1c, weight, BP, renal function, lipid panel, [[ALT]]/AST (especially for MASH problem)
* Personal or family history of MTC or [[MEN2]] — '''contraindicated''', do not start<ref name="ozempic-label"/>
* Personal or family history of MTC or [[MEN2]], '''contraindicated''', do not start<ref name="ozempic-label"/>
* Every 3 months for first year: HbA1c, weight, GI tolerability, signs of [[pancreatitis]] or [[gallbladder disease]]
* Every 3 months for first year: HbA1c, weight, GI tolerability, signs of [[pancreatitis]] or [[gallbladder disease]]
* Annual: renal function, lipids
* Annual: renal function, lipids
Line 93: Line 99:
* Inject SC in abdomen, thigh, or upper arm; rotate sites. Pen is single-patient, multi-dose.<ref name="ozempic-label"/>
* Inject SC in abdomen, thigh, or upper arm; rotate sites. Pen is single-patient, multi-dose.<ref name="ozempic-label"/>
* GI side effects almost always peak in first 2–4 weeks of any new dose level, then attenuate.<ref name="ozempic-label"/>
* GI side effects almost always peak in first 2–4 weeks of any new dose level, then attenuate.<ref name="ozempic-label"/>
* Eat smaller portions earlier in the day. Plate sizes will feel comically large after a few weeks — that is the medicine working, not a problem to fix.
* Eat smaller portions earlier in the day. Plate sizes will feel comically large after a few weeks, that is the medicine working, not a problem to fix.
* Hydrate aggressively (volume depletion → AKI is a real risk).<ref name="ozempic-label"/>
* Hydrate aggressively (volume depletion → AKI is a real risk).<ref name="ozempic-label"/>
* Resistance training during weight loss protects lean mass and is strongly encouraged.{{Citation needed}}
* Resistance training during weight loss protects lean mass and is strongly encouraged.{{Citation needed}}
Line 111: Line 117:
}}
}}


[[Category:MedCategory]]
[[Category:GLP-1 receptor agonists]]
[[Category:GLP-1 receptor agonists]]
[[Category:Antidiabetic medicines]]
[[Category:Antidiabetic medicines]]
[[Category:Anti-obesity medicines]]
[[Category:Anti-obesity medicines]]
[[Category:Novo Nordisk medicines]]
[[Category:Novo Nordisk medicines]]

Latest revision as of 18:00, 19 May 2026

GLP-1 receptor agonist · Antidiabetic · Anti-obesity · Cardiovascular risk reduction agent
Semaglutide
Ozempic (T2DM SC), Wegovy (obesity SC), Rybelsus (oral T2DM)
Semaglutide is a long-acting GLP-1 receptor agonist developed by Novo Nordisk, marketed as Ozempic (weekly subcutaneous, for type 2 diabetes mellitus),[1] Wegovy (weekly subcutaneous, for obesity, cardiovascular risk reduction in obesity without diabetes, and MASH with fibrosis),[2][6][7] and Rybelsus (daily oral tablet, for T2DM).[3] It is, by revenue, among the highest-grossing medicines on the planet as of 2024.[citation needed] Semaglutide is the second weekly GLP-1 RA from Novo Nordisk's incretin program (after liraglutide)[5] and the molecule that, more than any other, made obesity treatment a mainstream rather than a specialty intervention.[citation needed]

Experience

👥 No personal reports yet
⚕ No clinical reports yet

Log in to add your own experience.

Problems

Type 2 diabetes mellitus—
Obesity—
Cardiovascular risk reduction in obesity—
MASH with stage 2-3 fibrosis—
Chronic kidney disease in type 2 diabetes—
+ Add a problem

Titration strategies

Ozempic, standard T2DM titration0
0.25 mg SC weekly × 4 weeks (non-therapeutic; tolerance ramp only)

→ 0.5 mg SC weekly × ≥4 weeks → 1 mg SC weekly × ≥4 weeks if further glycemic control needed → 2 mg SC weekly (max) if needed[1]

Slower titration is reasonable in any patient with significant GI symptoms, holding at a tolerated dose for 8–12 weeks before advancing is standard practice.
Wegovy, standard obesity titration0
0.25 mg SC weekly × 4 weeks

→ 0.5 mg × 4 weeks → 1 mg × 4 weeks → 1.7 mg × 4 weeks → 2.4 mg weekly (maintenance)[2]

If a dose escalation is not tolerated, hold at the prior dose for an extra 4 weeks before advancing. Discontinue if patient cannot tolerate 1.7 mg after extended titration.[2]
Rybelsus, standard oral T2DM titration0
3 mg PO daily × 30 days (non-therapeutic ramp)

→ 7 mg PO daily × ≥30 days → 14 mg PO daily (max)[3]

Critical patient instruction: swallow whole, with no more than 120 mL (4 oz) of plain water, on an empty stomach, ≥30 minutes before the first food, drink, or any other oral medicine of the day.[3]

+ Add a titration strategy

Effects

Subjective effects vary considerably with dose and titration speed but reliably include:

  • Early satiety, meals feel "complete" at a fraction of prior intake[4]
  • Food noise quieting, the most commonly volunteered subjective change. Patients report that intrusive food-related thoughts simply stop.[citation needed]
  • Reduced alcohol craving, corroborated by observational and small RCT data; mechanism likely shared with food reward circuitry[8]
  • Nausea, dose-dependent, worst in first 1–2 weeks of any new dose level[1]
  • Constipation or diarrhea (variable, can alternate)[1]
  • Sulfurous eructation (a small but very real subgroup)[citation needed]
  • Reduced taste preference for fatty / sweet foods in many users[citation needed]

+ Add an effect

Pharmacokinetics

Chemistry. 31-amino-acid acylated peptide analog of human GLP-1 (7–37), with Aib substitution at position 8 (blocks DPP-4 cleavage) and a C18 fatty diacid linked via γGlu-2×OEG spacer at Lys26 (drives albumin binding → ~165 h half-life)[5]

Acylation with a C18 fatty diacid drives non-covalent binding to serum albumin, slowing renal clearance and DPP-4 access. The Aib8 substitution renders the peptide DPP-4-resistant. Resulting terminal half-life ~165 h means once-weekly subcutaneous dosing produces near-steady-state plasma levels.[5]

Oral semaglutide (Rybelsus) is co-formulated with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), a permeation enhancer that transiently raises gastric pH and protects the peptide locally, yielding ~0.4–1% bioavailability, which is sufficient at 14 mg daily to match Ozempic 0.5 mg weekly for glycemic effect (but not for weight loss).[3][9] Strict fasting administration is mandatory; any concurrent food or beverage destroys absorption.[3]

Predominantly catabolic clearance via proteolysis; renal and hepatic impairment do not require dose adjustment.[1] No CYP-mediated metabolism, so the interaction profile is dominated by gastric emptying effects on other oral medicines, not pharmacokinetic competition.[1]

Pharmacodynamics

Receptor pharmacology. Selective long-acting agonist of the GLP-1 receptor (class B GPCR). Produces glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, hypothalamic appetite suppression, and direct cardiovascular and renal protective effects.[10]

At maintenance doses semaglutide produces:

  • HbA1c reduction of ~1.5–2.0 percentage points (Ozempic 1 mg)[11]
  • Weight loss of ~6 kg (Ozempic 1 mg, T2DM)[11] to ~14.9% body weight (Wegovy 2.4 mg, obesity without T2DM, STEP-1)[4]
  • Systolic BP reduction of ~5 mmHg[6]
  • Modest LDL-C reduction, larger triglyceride reduction[citation needed]
  • 20% relative risk reduction in MACE in obesity without T2DM (SELECT)[6]
  • 24% relative risk reduction in kidney + CV composite in T2DM + CKD (FLOW)[12]

    Interactions

No interactions reported yet.

Pregnancy and lactation

Category formerly X-equivalent; current FDA labeling: avoid in pregnancy.[1] Animal embryofetal toxicity is well-documented.[1] Because the half-life is ~1 week, current guidance is to discontinue at least 2 months before any planned conception.[1]

Postpartum: not recommended during breastfeeding pending more data; small molecule transfer to milk is unlikely given peptide structure but not formally characterized.[citation needed]

Importantly: semaglutide is not a contraceptive, and the medicine may restore ovulation in patients with PCOS or obesity-associated anovulation.[citation needed] Patients of childbearing potential should be counseled about contraception before starting.

Monitoring

  • Baseline: HbA1c, weight, BP, renal function, lipid panel, ALT/AST (especially for MASH problem)
  • Personal or family history of MTC or MEN2, contraindicated, do not start[1]
  • Every 3 months for first year: HbA1c, weight, GI tolerability, signs of pancreatitis or gallbladder disease
  • Annual: renal function, lipids
  • Pre-procedure: hold weekly dose ≥7 days before any planned anesthesia (per ASA 2024 guidance) due to delayed gastric emptying / aspiration risk[13]

    Patient counseling

  • Slow titration is non-negotiable for tolerability. Patients who insist on faster ramps usually quit from GI side effects.
  • Inject SC in abdomen, thigh, or upper arm; rotate sites. Pen is single-patient, multi-dose.[1]
  • GI side effects almost always peak in first 2–4 weeks of any new dose level, then attenuate.[1]
  • Eat smaller portions earlier in the day. Plate sizes will feel comically large after a few weeks, that is the medicine working, not a problem to fix.
  • Hydrate aggressively (volume depletion → AKI is a real risk).[1]
  • Resistance training during weight loss protects lean mass and is strongly encouraged.[citation needed]
  • If a weekly dose is missed: take within 5 days; if >5 days, skip and resume on the next regular day.[1]
  • Avoid alcohol during titration weeks (compounds nausea).
  • Pregnancy planning: stop ≥2 months before trying to conceive.[1]
  • Surgery: tell every anesthesiologist and surgeon you are on a weekly GLP-1 RA. Hold dose 7 days pre-op.[13]

    Relevant anecdote

0 0 0 0

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

See also

GLP-1 receptor agonist · Tirzepatide · Liraglutide · Dulaglutide · Exenatide · Type 2 diabetes mellitus · Obesity · MASH

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 US FDA. Ozempic (semaglutide) prescribing information. Novo Nordisk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s019lbl.pdf
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 US FDA. Wegovy (semaglutide) prescribing information. Novo Nordisk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
  3. ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 US FDA. Rybelsus (semaglutide) prescribing information. Novo Nordisk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf
  4. ↑ 4.0 4.1 4.2 Wilding JPH et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP-1). NEJM 384:989. doi:10.1056/NEJMoa2032183
  5. ↑ 5.0 5.1 5.2 5.3 Lau J, Bloch P, Schäffer L et al. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem 58(18):7370–80. doi:10.1021/acs.jmedchem.5b00726
  6. ↑ 6.0 6.1 6.2 Lincoff AM et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). NEJM 389:2221–32. doi:10.1056/NEJMoa2307563
  7. ↑ Newsome PN et al. (2025). Semaglutide in MASH (ESSENCE). FDA approval basis. [citation needed]
  8. ↑ Wang W, Volkow ND, Berger NA et al. (2024). Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun 15:4548. doi:10.1038/s41467-024-48780-6
  9. ↑ Buckley ST, Bækdal TA, Vegge A et al. (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med 10(467):eaar7047. doi:10.1126/scitranslmed.aar7047
  10. ↑ Drucker DJ (2022). GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab 57:101351. doi:10.1016/j.molmet.2021.101351
  11. ↑ 11.0 11.1 Marso SP et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). NEJM 375:1834–44. doi:10.1056/NEJMoa1607141
  12. ↑ Perkovic V et al. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). NEJM 391:109. doi:10.1056/NEJMoa2403347
  13. ↑ 13.0 13.1 Kindel TL et al. (2024). Perioperative GLP-1 receptor agonist safety guidance. Surg Obes Relat Dis 20(12):1183–8.
Pharmacy
Starting dose
Ozempic: 0.25 mg SC weekly × 4 wk[1] · Wegovy: 0.25 mg SC weekly × 4 wk[2] · Rybelsus: 3 mg PO daily × 30 d[3]
Preparations
Pre-filled multi-dose pen (0.25 / 0.5 / 1 / 2 mg, Ozempic;[1] 0.25 / 0.5 / 1 / 1.7 / 2.4 mg, Wegovy[2]) · Oral tablet 3 / 7 / 14 mg co-formulated with SNAC absorption enhancer (Rybelsus)[3]
US FDA Max
2 mg/wk SC (Ozempic)[1] · 2.4 mg/wk SC (Wegovy)[2] · 14 mg PO daily (Rybelsus)[3]
Common uses
Common uses
Classification(s)
Classes
GLP-1 receptor agonist · Antidiabetic · Anti-obesity · Cardiovascular risk reduction agent
Pharmacology
Routes
Subcutaneous (abdomen, thigh, upper arm)[1] · Oral (Rybelsus only, on empty stomach with ≤120 mL water, ≥30 min before any food/drink/other oral medicine)[3]
Onset
Glycemic effect within days;[citation needed] full weight effect over months[4]
Duration
~7 days (weekly SC dosing)[1] · ~24 h (oral)[3]
Half-life
~165 hours (~1 week), among the longest of any GLP-1 RA[5]
Bioavailability
SC ~89%[citation needed] · Oral ~0.4–1% (SNAC-enhanced)[3]
Pregnancy
Avoid. Discontinue ≥2 months before planned pregnancy due to long half-life. Animal data show embryofetal harm.[1] Not contraceptive, but rapid weight loss + improved ovulation may unmask fertility in PCOS.[citation needed]
Legal status
Rx-only;[1] not a controlled substance
Purported mechanism
Long-acting agonist of the GLP-1 receptor.
Pharmacopedia is intended for reference. Nothing here is advice. In an emergency call 911; US Poison Control 1-800-222-1222. See the full disclaimer.
Retrieved from "https://pharmacopedia.wiki/index.php?title=Semaglutide&oldid=4691"